Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

CISATRACURIUM BESYLATE injection, solution USA - engelsk - NLM (National Library of Medicine)

cisatracurium besylate injection, solution

hospira, inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate injection multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate injection is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate injection single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug-associated risk of

CISATRACURIUM BESYLATE injection USA - engelsk - NLM (National Library of Medicine)

cisatracurium besylate injection

zydus lifesciences limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . risk summary there are no adequate and well-controlled studies of cisatracurium besylate in pregnant women. animal studies conducted in rats administered cisatracurium besylate during organogen

CISATRACURIUM BESYLATE injection USA - engelsk - NLM (National Library of Medicine)

cisatracurium besylate injection

zydus pharmaceuticals usa inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . risk summary there are no adequate and well-controlled studies of cisatracurium besylate in pregnant women. animal studies conducted in rats administered cisatracurium besylate during organogen

Cisatracurium Accordpharma 2 mg/ml inj./inf. sol. i.v. vial Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium accordpharma 2 mg/ml inj./inf. sol. i.v. vial

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Accordpharma 2 mg/ml inj./inf. sol. i.v. vial Belgien - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium accordpharma 2 mg/ml inj./inf. sol. i.v. vial

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium